Janssen Pharmaceutica Nv

Ortho-mcneil Pharmaceutical Corp.

Other

Ortho Pharmaceutical Corporation

Steven P Meduna

Jianmei Wei

Hui Cai

James Patrick Edwards

Barbara A Pio

Kevin L Tays

Cheryl A Grice

Haripada Khatuya

Darin J Gustin

J Guy Breitenbucher

John M Keith

Steven D Goldberg

Mary Pat Beavers

Michael D Hack

Jing Liu

Alec D Lebsack

Natalie Anne Hawryluk

Kelly J McClure

Wendy Eccles

Mark D Rosen

Paul J Krawczuk

William Moore Jones

Anne E Fitzgerald

Robin L Thurmond

Stefan McCarver

Alexander Valdes

Neelakandha S Mani

Xiaohua Xue

Timothy B Rhorer

Steven Loskot

Douglas Behenna

Daniel J Pippel

Genesis M Bacani

Lars Karlsson

Alice Lee-Dutra

Connor L Martin

Zachary S Sales

Siquan Sun

Yin Gu

Ronald L Wolin

Brad M Savall

Craig R Woods

Clark A Sehon

Frank Chavez

Xiaohu Zhang

Alexander Raymond Rovira

Paul J Dunford

Andrew J Greenspan

Jorge A Quiroz

Christopher R Butler

Deane Gordon

Luke E Hanna

David A Kummer

Jennifer Diane Venable

Brock T Shireman

Dongpei Wu

Virginia M Tanis

Charlotte Pooley Deckhut

Dougas C Behenna

Kristen Song

Alexander Rovira

Kelly J Mcclure

The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R, R, R, and Rare defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.

Imidazopyridazine IL-17 inhibitor compounds

The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R, R, R, Rand Rare defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.

Imidazopyridazines as modulators of IL-17

The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R, L and Rare as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention. 

Flap modulators

The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R, L and Rare as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.

The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R, R, R, R', L, W, and V are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.

FLAP modulators

The present invention relates to compounds of Formula (I), or a form thereof wherein ring A, R, R, R, R', L, W, and V are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention. 

Diamino-pyridine, pyrimidine and pyridazine compounds which may be used as Hreceptor modulators, and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by Hreceptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.

[object Object]

Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor

Substituted pyrazoles, methods of manufacturing them, compositions containing them, and methods of using them to treat, for example, autoimmune diseases mediated by cathepsin S.

Substituted pyrazoles

Growing community of inventors

San Diego, CA, United States of America

Steven P Meduna